Zurig (Febuxostat) 40mg Efficacy and Safety Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid. The investigators conducted an interventional, two-arm, randomized, open label pilot study on patients with serum urate level ≥ 6.8 mg/dL. Patients were treated with Febuxostat 40 mg Tablets or Allopurinol 300 mg Tablets once daily dose for 90 days to determine the efficacy and safety of Febuxostat in comparison with Allopurinol in Hyperuricemic Subjects with or without Gout.
Epistemonikos ID: c93508538b08ea3a0ed2eb35e5074b3f4120ddb4
First added on: May 12, 2024